Should I buy or sell Medpace stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks .

What is Medpace's stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they predict the company's stock price to reach $382.00 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts .

How have MEDP shares performed in 2024?

Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP shares have increased by 21.4% and is now trading at $372.00. View the best growth stocks for 2024 here .

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our MEDP earnings forecast .

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, February, 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.24. The company earned $498.40 million during the quarter, compared to analyst estimates of $498.72 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. Medpace's revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 EPS.

What ETFs hold Medpace's stock?

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Argent Mid Cap ETF (AMID) , Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) , Invesco S&P MidCap Quality ETF (XMHQ) , First Trust Health Care AlphaDEX Fund (FXH) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) and Invesco S&P MidCap 400 Pure Growth ETF (RFG) .

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 10.180-10.870 for the period, compared to the consensus estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com . August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA) , Exact Sciences (EXAS) , Block (SQ) , Baidu (BIDU) , JD.com (JD) , Advanced Micro Devices (AMD) , Bilibili (BILI) , Alibaba Group (BABA) , Cisco Systems (CSCO) and Intuitive Surgical (ISRG) .

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%) and Norden Group LLC (0.10%). Insiders that own company stock include Ashley M Keating , August J Troendle, August J Troendle , Kevin M Brady , Medpace Investors, Llc, Peter J O'malley, Robert O Kraft , Stephen P Ewald , Susan E Burwig , Tom C King and Wedbush Securities Inc. View institutional ownership trends .

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MEDP

Medpace (MEDP) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MEDP Stock Alerts

$372.00

-2.32 (-0.62%)

(As of 04/19/2024 ET)

Compare

Today's Range: $368.37
▼
$377.86
50-Day Range: $324.21
▼
$413.31
52-Week Range: $185.43
▼
$419.42

Volume: 221,633 shs
Average Volume: 172,626 shs
Market Capitalization: $11.53 billion

P/E Ratio: 41.89
Dividend Yield: N/A
Price Target: $382.00

Get Medpace alerts:

Medpace MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 2.7% Upside
$382.00 Price Target
Short Interest: Healthy
3.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.90
Based on 8 Articles This Week
Insider Trading: Selling Shares
$76.65 M Sold Last Quarter
Proj. Earnings Growth: 20.89%
From $10.53 to $12.73 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.49 out of 5 stars

Medical Sector

90th out of 912 stocks

Commercial Physical Research Industry

5th out of 12 stocks

1.4

Analyst's Opinion

Consensus Rating
Medpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Medpace has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.82% of the float of Medpace has been sold short.
Short Interest Ratio / Days to Cover
Medpace has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Medpace has recently decreased by 1.76%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Medpace does not currently pay a dividend.
Dividend Growth
Medpace does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Medpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Medpace is -0.62.

2.7

News and Social Media Coverage

News Sentiment
Medpace has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Medpace this week, compared to 6 articles on an average week.
Search Interest
Only 6 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,651,647.00 in company stock.
Percentage Held by Insiders
20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Medpace are expected to grow by 20.89% in the coming year, from $10.53 to $12.73 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Medpace is 41.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medpace is 41.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.41.
Price to Earnings Growth Ratio
Medpace has a PEG Ratio of 1.98. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Medpace has a P/B Ratio of 20.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MEDP Stock News Headlines

March 20, 2024 | insidertrades.com

Insider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) VP Sells 102 Shares of Stock

April 19, 2024 | msn.com

Medpace Q1 2024 Earnings Preview

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | msn.com

An iconic bar returns (and the 3 best things I ate last week)

April 17, 2024 | markets.businessinsider.com

Medpace Holdings Inc hosts conference call for investors

April 15, 2024 | americanbankingnews.com

Financial Survey: Medpace (NASDAQ:MEDP) and OneMedNet (NASDAQ:ONMD)

April 15, 2024 | americanbankingnews.com

Medpace (MEDP) to Release Quarterly Earnings on Monday

April 12, 2024 | americanbankingnews.com

Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of "Moderate Buy" by Analysts

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | benzinga.com

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,800 Today

April 8, 2024 | finance.yahoo.com

Estimating The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

April 5, 2024 | finance.yahoo.com

Medpace Holdings (MEDP) is Maintaining a Healthy Margin Profile

March 28, 2024 | businesswire.com

Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024

March 28, 2024 | businesswire.com

Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024

March 28, 2024 | msn.com

Alara is Madisonville's newest American restaurant, latest from popular restaurant group

March 27, 2024 | msn.com

New restaurant opens in Cincinnati's Madisonville neighborhood

March 25, 2024 | bizjournals.com

Looking Glass Hospitality announces menu, hours for new $6.5M upscale restaurant, Alara

March 22, 2024 | finance.yahoo.com

Should You Invest in Medpace (MEDP)?

March 22, 2024 | finance.yahoo.com

Investors in Medpace Holdings (NASDAQ:MEDP) have seen enviable returns of 609% over the past five years

March 19, 2024 | finance.yahoo.com

Does Medpace Holdings (MEDP) Have The Potential to Maintain Strong Growth?

March 18, 2024 | insidermonkey.com

Insiders Are Selling These 5 Stocks in 2024

March 17, 2024 | bizjournals.com

Convergence of factors powers the innovative ecosystem’s competitive advantage in Ohio

March 16, 2024 | finance.yahoo.com

MEDP Apr 2024 580.000 call

March 15, 2024 | bizjournals.com

Five things to know, and Cincinnati chili in the Windy City? I'm a skeptic

March 14, 2024 | bizjournals.com

Looking Glass Hospitality announces opening date, menu for newest restaurant venture, Alara

March 12, 2024 | uk.finance.yahoo.com

Patient Recruitment and Retention Services Global Market Report 2024

March 11, 2024 | seekingalpha.com

Medpace: Exceptional Performance, Almost Fully Priced In

See More Headlines

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/12/2024
Today: 4/20/2024
Next Earnings (Confirmed): 4/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Commercial physical research
Sub-Industry: N/A
Current Symbol: NASDAQ:MEDP
CUSIP: N/A
CIK: 1668397
Web: www.medpace.com
Phone: (513) 579-9911
Fax: 513-579-0444
Employees: 5,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $382.00
High Stock Price Target: $452.00
Low Stock Price Target: $273.00
Potential Upside/Downside: +2.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.88
Trailing P/E Ratio: 41.89
Forward P/E Ratio: 35.33
P/E Growth: 1.98
Net Income: $282.81 million
Net Margins: 15.00%
Pretax Margin: 17.80%
Return on Equity: 63.98%
Return on Assets: 19.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.64
Quick Ratio: 0.64

Sales & Book Value

Annual Sales: $1.89 billion
Price / Sales: 6.11
Cash Flow: $10.01 per share
Price / Cash Flow: 37.15
Book Value: $18.22 per share
Price / Book: 20.42

Miscellaneous

Outstanding Shares: 30,983,000
Free Float: 24,693,000
Market Cap: $11.53 billion
Optionable: Optionable
Beta: 1.38

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. August James Troendle M.D. (Age 68)
Chairman & CEO
Comp: $1.68M
Mr. Jesse J. Geiger BBA (Age 50)
CPA, President
Comp: $876.92k
Mr. Kevin M. Brady (Age 49)
CFO & Treasurer
Comp: $636.58k
Ms. Susan E. Burwig BSN (Age 61)
MA, Executive Vice President of Operations
Comp: $1M
Mr. Stephen P. Ewald J.D. (Age 55)
Chief Compliance Officer, General Counsel & Corporate Secretary
Comp: $826.17k
Brandon Ebken
Chief Information Officer
Ms. Lauren Morris
Associate Director of Investors Relations
Mr. Todd Meyers
Vice President of Business Development & Marketing
John T. Wynne MBA
Senior Vice President of Commercial Operations & Clinical Pharmacology Unit
Mr. Reinilde Heyrman M.D. (Age 63)
Chief Medical Officer of Medical Department

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings or view top-rated stocks.
What is Medpace's stock price target for 2024?: 4 Wall Street analysts have issued 12 month target prices for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they predict the company's stock price to reach $382.00 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.
How have MEDP shares performed in 2024?: Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP shares have increased by 21.4% and is now trading at $372.00.
View the best growth stocks for 2024 here.
When is Medpace's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our MEDP earnings forecast.
How can I listen to Medpace's earnings call?: Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Medpace's earnings last quarter?: Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, February, 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.24. The company earned $498.40 million during the quarter, compared to analyst estimates of $498.72 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. Medpace's revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 EPS.
What ETFs hold Medpace's stock?: ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM) and Invesco S&P MidCap 400 Pure Growth ETF (RFG).

What guidance has Medpace issued on next quarter's earnings?: Medpace issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 10.180-10.870 for the period, compared to the consensus estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.
What is August Troendle's approval rating as Medpace's CEO?: 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Medpace own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).
When did Medpace IPO?: Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?: Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%) and Norden Group LLC (0.10%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.
How do I buy shares of Medpace?: Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial